Jazz Pharmaceuticals (JAZZ) — insider trading
Health Care · NASDAQ
Jazz Pharmaceuticals (JAZZ) has 14 reported SEC Form 4 insider transactions in our data, including 6 open-market sales among the most recent 14 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $240.47 | $1.44M | Form 4 |
| 2026-06-30 | Johnson Philip L | Officer (EVP & Chief Financial Officer) | Shares withheld for taxes / exercise cost | 3,343 | $237.72 | $794.7K | Form 4 |
| 2026-06-30 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Shares withheld for taxes / exercise cost | 2,678 | $237.72 | $636.6K | Form 4 |
| 2026-06-30 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Shares withheld for taxes / exercise cost | 3,764 | $237.72 | $894.8K | Form 4 |
| 2026-06-30 | GALA RENEE D | Officer (President & CEO) | Shares withheld for taxes / exercise cost | 4,835 | $237.72 | $1.15M | Form 4 |
| 2026-06-30 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 2,527 | $237.72 | $600.7K | Form 4 |
| 2026-06-15 | Smith Mark Douglas | Director | Open-market sale | 1,157 | $230.55 | $266.7K | Form 4 |
| 2026-06-10 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Open-market sale | 1,200 | $231.83 | $278.2K | Form 4 |
| 2026-06-03 | GALA RENEE D | Officer (President & CEO) | Bona fide gift | 600 | $0.00 | $0 | Form 4 |
| 2026-06-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $235.12 | $1.41M | Form 4 |
| 2026-05-28 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion (derivative) | 6,907 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Open-market sale | 6,907 | $235.41 | $1.63M | Form 4 |
| 2026-05-28 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion | 6,907 | $109.45 | $756.0K | Form 4 |
| 2026-05-28 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Open-market sale | 1,192 | $236.97 | $282.5K | Form 4 |
Ask the chat about JAZZ's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Jazz Pharmaceuticals (JAZZ).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.